Dr. Janice Mehnert on Why it's a Challenge to Identify Biomarkers for Immunotherapy

Janice Mehnert, MD
Published: Friday, Oct 28, 2016


Janice Mehnert, MD, medical oncologist, director, Phase I and Developmental Therapeutics Program, Rutgers Cancer Institute of New Jersey, discusses challenges with identifying effective biomarkers in for immunotherapy agents. 

The immune system is in constant flux, and because of that everyboyd’s immune response is different, says Mehnert.
 
The immune response that is induced by checkpoint inhibitors is going to vary from patient to patient, and it also varies from disease to disease. Part of the challenge is that there are now drugs that have activity in many different tumor types, which is sort of an unprecedented paradigm in oncology, says Mehnert.

Immunotherapies do not work the same in all of those tumor types, even toxicity may be different from disease type to disease type. This may mean that doses will have to be different for different diseases. This is not something that most oncologists are used, says Mehnert.
 
The immune system is very dynamic which is another challenge in determining biomarkers, says Mehnert.
 
Immunotherapy biomarker testing is not quite as clear-cut as other genomics tests, where it’s possible to do PCR and find a mutation, and really have a clean line between target and treatment, says Mehnert.

Janice Mehnert, MD, medical oncologist, director, Phase I and Developmental Therapeutics Program, Rutgers Cancer Institute of New Jersey, discusses challenges with identifying effective biomarkers in for immunotherapy agents. 

The immune system is in constant flux, and because of that everyboyd’s immune response is different, says Mehnert.
 
The immune response that is induced by checkpoint inhibitors is going to vary from patient to patient, and it also varies from disease to disease. Part of the challenge is that there are now drugs that have activity in many different tumor types, which is sort of an unprecedented paradigm in oncology, says Mehnert.

Immunotherapies do not work the same in all of those tumor types, even toxicity may be different from disease type to disease type. This may mean that doses will have to be different for different diseases. This is not something that most oncologists are used, says Mehnert.
 
The immune system is very dynamic which is another challenge in determining biomarkers, says Mehnert.
 
Immunotherapy biomarker testing is not quite as clear-cut as other genomics tests, where it’s possible to do PCR and find a mutation, and really have a clean line between target and treatment, says Mehnert.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Publication Bottom Border
Border Publication
x